-
Non Regulatory November 26, 2021Oasmia to present at the Erik Penser Bank Life Science Day on December 2
-
Non Regulatory November 26, 2021Oasmia to present at Stora Aktiedagen Stockholm on December 2
-
Regulatory November 18, 2021Interim report for the period January 1, 2021 – September 30, 2021
Oasmia Pharmaceutical published its Q3 2021 report on November 18, 2021, at 08.00 am CET.
The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
;
Today we published our Q3 Interim Report highlighting Oasmia’s continuing progress.
Read the full report on our website here:
#oncology
Interim report for the period January 1, 2021 – September 30, 2021 - Oasmia
SIGNIFICANT EVENTS DURING THE THIRD QUARTER
bit.ly
Our advanced ovarian programme #Cantrixil has been featured in this insightful article in The Canberra Times. Read more here:
#oncology #ovariancancer #hardtotreatcancer
New Australian cancer study offers hope
An Australian oncologist is to conduct a phase II study in a bid to progress vital research into the treatment ...
bit.ly